Sparsentan Insert: Indications, Dosage and Administration, Dose Adjustment, Adverse

Sparsentan, developed by Travere Therapeutics, is a dual receptor antagonist that significantly reduces proteinuria by simultaneously blocking endothelin type A (ETA) and angiotensin II type 1 (AT1) receptors. The drug received accelerated approval from the FDA in 2023 for the treatment of IgA nephropathy and was upgraded to full approval in 2024, becoming the first targeted therapy approved to the decline in kidney function in adults with primary IgA nephropathy.

Sparsentan Indications

IgA Nephropathy

Sparsentan is indicated to slow the decline in kidney function in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk of disease progression.

Sparsentan Dosage and Administration

1. Recommended Dosage

The initial dosage of Sparsentan is 200 mg once daily for 14 days. After 14 days, the dosage may be increased to 400 mg once daily based on tolerability.

When resuming Sparsentan after interruption, consider dose titration starting at 200 mg once daily; after 14 days, increase to 400 mg once daily.

2. Dosage Modifications

If a patient treated with Sparsentan experiences elevations in AST or ALT, adjust monitoring and treatment accordingly. Do not resume Sparsentan in patients who develop clinical symptoms of hepatotoxicity or whose liver enzymes and bilirubin levels have not returned to baseline.

Due to space limitations, please refer to the official drug label for detailed information. All medication usage should be followed as per a physician's guidance.

Sparsentan Adverse Reactions

Common Adverse Reactions (≥5%)

Common adverse reactions to Sparsentan include peripheral edema, hypotension (including orthostatic hypotension), dizziness, hyperkalemia, anemia, and acute kidney injury.

Due to space limitations, please refer to the official drug label for detailed information. All medication usage should be followed as per a physician's guidance.

Sparsentan Warnings and Precautions

1. Hepatotoxicity

Reports of hepatotoxicity have occurred with Sparsentan. Monitor AST, ALT, and total bilirubin before initiating Sparsentan, monthly for the first year of treatment, and every 3 months thereafter.

2. Fetal/Neonatal Morbidity and Mortality

Based on animal findings, Sparsentan can cause fetal harm and is contraindicated in pregnant women. Perform a pregnancy test before starting Sparsentan, monthly during treatment, and for one month after discontinuing Sparsentan. Advise females of reproductive potential to use effective contraception before starting Sparsentan, during treatment, and for one month after discontinuation. Inform patients about the potential risk to a fetus if Sparsentan is used during pregnancy.

3. Hypotension

Hypotension has been reported with Sparsentan. Consider eliminating or adjusting other antihypertensive medications and maintain appropriate volume status in patients at risk for hypotension. If hypotension occurs despite elimination or reduction of other antihypertensives, consider reducing or interrupting the Sparsentan dose. Sparsentan may be resumed once blood pressure is stable.

4. Acute Kidney Injury

Acute kidney injury may occur; risk may be increased in patients whose renal function depends on the activity of the renin-angiotensin-aldosterone system (e.g., patients with renal artery stenosis, chronic kidney disease, severe congestive heart failure, or volume depletion). Monitor renal function periodically. Consider withholding or discontinuing Sparsentan in patients who experience a clinically significant decrease in renal function.

5. Hyperkalemia

Risk is increased in patients with advanced kidney disease or those taking concomitant potassium-increasing agents (e.g., potassium supplements, potassium-sparing diuretics, potassium-containing salt substitutes). Monitor serum potassium periodically and manage appropriately. If hyperkalemia occurs, consider dose reduction or discontinuation of Sparsentan.

6. Fluid Retention

Fluid retention has been reported. Sparsentan has not been studied in patients with heart failure. If clinically significant fluid retention develops, determine the underlying cause and whether initiating or modifying diuretic therapy is needed, then consider adjusting the Sparsentan dosage.